Genesis IBRC India Peer Comparison

BSE: 514336

₹38.93

₹1.54 (4.12%)

As on 06-Nov-2026IST

Market cap

₹763 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

4

Div. Yield

0 %

Edit

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Market cap (₹ Cr)	763	2,218	162	51,539	37,300
Revenue (₹ Cr)	--	429	71	2,046	5,053
Net Profit (₹ Cr)	-0.86	80.36	5.14	613.98	613.08
Net Margin (%)	-2,391.67	18.25	7.16	27.72	11.89
RoE (%)	-3.56	17.20	5.85	19.97	15.63
Price to Earnings	--	27.61	46.57	83.94	60.32
Price-To-Book	4.00	4.51	2.47	15.71	8.63

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Operating Revenue	--	407.29	61.54	2,124.33	4,410.27
Total Income	0.04	416.28	62.51	2,280.12	4,514.67
Total Expenditure	0.75	265.77	51.53	1,290.36	3,486.05
EBITDA	-0.75	141.52	10.01	833.97	924.22
Depreciation	--	43.77	6.64	134.07	222.54
EBIT	-0.75	97.75	3.36	699.90	701.68
Interest	0.00	1.17	2.23	7.06	90.05
Other Income	0.04	8.99	0.97	155.78	104.41
Exceptional Items	--	-1.62	--	-24.39	-1.02
Profit before Tax	-0.71	103.95	2.09	824.24	715.02
Provision for Tax	--	26.44	1.06	232.45	160.95
Profit after Tax	-0.71	77.51	1.03	591.79	554.07

Liabilities (₹ Cr)

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Shareholder's Funds	40.07	456.87	71.72	3,042.52	3,961.57
Minority Interest	--	--	1.23	--	22.71
Non-Current Liabilities	--	33.55	13.74	33.74	1,277.95
Current Liabilities	5.24	65.52	19.89	529.71	627.13
Total Liabilities	45.31	562.23	106.59	3,633.29	5,905.00

Assets (₹ Cr)

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Non-Current Assets	--	331.07	56.72	1,598.82	4,214.44
Current Assets	45.31	224.87	49.87	2,007.15	1,674.92
Total Assets	45.31	562.23	106.59	3,633.29	5,905.00
Total Debt*	0.00	3.33	17.16	51.07	631.08
Net Current Assets	40.07	159.35	29.98	1,477.43	1,047.79
Contingent Liabilities	--	1.95	--	90.20	100.01

Cashflow (₹ Cr)

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Cash From Operating Activities	5.10	147.14	0.42	844.49	714.39
Cash Flow from Investing Activities	--	-129.67	-9.98	-701.62	-1,089.11
Cash from Financing Activities	32.25	-10.35	18.83	-40.00	271.85
Net Cash Inflow / Outflow	37.35	7.12	9.26	102.87	-102.87

Ratios

Profitability Ratios

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
ROCE (%)	-2.94	24.81	5.61	29.62	19.38
ROE (%)	-2.94	18.87	1.90	21.98	15.12
ROA (%)	-2.64	15.25	1.12	18.06	10.43
EBIT Margin (%)	--	36.95	17.84	46.59	23.32
Net Margin (%)	-2,042.00	18.62	1.65	25.95	12.27
Cash Profit Margin (%)	--	29.78	12.47	33.25	17.61

Growth Ratios

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Revenue Growth (%)	--	18.40	31.37	15.17	19.44
EBIT Growth (%)	-120.39	19.27	33.56	30.79	6.57
Net Profit Growth (%)	-120.39	16.11	1,651.36	31.14	15.11
EPS Growth (%)	-105.86	15.59	658.14	30.53	15.54
Book Value Growth (%)	369.59	20.79	47.32	26.67	16.51

Valuation Ratios

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Price / Earnings	0.00	21.95	110.78	62.29	46.44
Price / Book Value	11.18	3.78	1.97	12.25	6.55
Dividend Yield (%)	0.00	0.53	0.00	0.30	0.05
EV/EBITDA	-574.48	10.89	12.31	37.02	24.64
Market Cap (₹ Cr)	--	1,701.05	127.48	36,865.25	25,841.07

Solvency Ratios

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Debt to Equity	0.00	0.01	0.27	0.02	0.16
Short term debt to equity ratio	--	--	0.05	0.00	--
Current Ratio	8.64	3.43	2.51	3.79	2.67
Quick Ratio	8.64	2.97	2.35	3.55	2.54
Interest Coverage	-7,146.00	90.08	1.94	117.83	8.94

Operating Efficiency Ratios

	Genesis IBRC India	Vimta Labs	Jeevan Scientific	Anthem Biosciences	Global Health
Debtors to sales (%)	--	25.95	33.63	27.80	9.32
Asset Turnover	0.00	0.80	0.67	0.67	0.83
Receivable days	--	94.97	108.65	87.02	29.09
Inventory Days	--	24.65	13.78	38.87	6.05
Payable days	--	--	348.18	41.63	80.04
Cash Conversion Cycle	--	--	-225.76	84.26	-44.90

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.